ViaDerma is developing products in many fields of use, including: Topical antibiotics- $6 billion/year Toenail antifungal drugs- $3 billion/year Diabetic amputations- $3 billion/year Global acne- $2.8 million in 2009, estimates of $3.02 billion by 2016 Psoriasis- $2.4 billion in 2010, estimates of over $7.3 billion by 2015 Eczema- $2.5 billion in 2014 Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management.
DD makes the charts, the charts don't make the DD.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.